1. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
- Author
-
Wittrock J, Schweizer P, and Girgert R
- Subjects
- Alkyl and Aryl Transferases metabolism, Cell Division drug effects, Farnesyltranstransferase, Gene Amplification, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic physiology, Gene Silencing drug effects, Gene Silencing physiology, Genes, myc drug effects, Humans, Insulin-Like Growth Factor II biosynthesis, MAP Kinase Signaling System drug effects, MAP Kinase Signaling System physiology, Methionine pharmacology, Mitogen-Activated Protein Kinase 3, Mitogen-Activated Protein Kinases metabolism, Neuroblastoma enzymology, Neuroblastoma metabolism, Neuroblastoma pathology, Proto-Oncogene Proteins c-myc biosynthesis, Proto-Oncogene Proteins c-myc genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, Receptors, Somatomedin biosynthesis, Recombinant Proteins pharmacology, ras Proteins antagonists & inhibitors, ras Proteins genetics, ras Proteins metabolism, Alkyl and Aryl Transferases antagonists & inhibitors, Enzyme Inhibitors pharmacology, Genes, myc genetics, Insulin-Like Growth Factor II pharmacology, Methionine analogs & derivatives, Neuroblastoma genetics, ras Proteins physiology
- Abstract
Genetic aberrations are the primary events leading to carcinogenesis in various tissues and are characteristic for certain tumor types. Amplification of N-myc and deletion of 1p significantly correlate with poor prognosis of neuroblastoma patients. Very little informations is available on the regulation of N-myc expression by external factors. Insulin-like growth factor-II (IGF-II) has been identified as an autocrine growth factor in neuroblastoma. Four neuroblastoma cell lines were examined for their expression of IGF-II and IGF-receptor. Stimulation of neuroblastoma cells with IGF-II leads to an increased activity of the MAP-kinase Erk1, an induction of N-myc expression and an enhanced proliferation rate. In order to disrupt the signal transduction of the IGF-receptor, we inactivated the Ras-proteins in neuroblastoma cells by inhibition of the farnesyl-protein transferase by FTI-277. This inactivation prevented activation of MAP-kinase Erk1 and induction of N-myc expression by IGF-II. Inactivation of Ras by farnesyltransferase inhibitors might become a promising new approach in future treatments of neuroblastoma tumors.
- Published
- 2002